| 2.69 -0.03 (-1.1%) | 03-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.67 | 1-year : | 4.29 |
| Resists | First : | 3.15 | Second : | 3.67 |
| Pivot price | 2.61  |
|||
| Supports | First : | 2.42 |
Second : | 1.98 |
| MAs | MA(5) : | 2.79 |
MA(20) : | 2.49 |
| MA(100) : | 2.24 |
MA(250) : | 2.68 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 58.8 |
D(3) : | 66.2 |
| RSI | RSI(14): 61 |
|||
| 52-week | High : | 4.59 | Low : | 1.35 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ELDN ] has closed below upper band by 39.7%. Bollinger Bands are 37.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.88 - 2.9 | 2.9 - 2.92 |
| Low: | 2.61 - 2.63 | 2.63 - 2.65 |
| Close: | 2.65 - 2.69 | 2.69 - 2.72 |
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Wed, 11 Mar 2026
ELDN: Tegoprubart advances with strong safety, phase 3 plans, and expanding transplant indications - TradingView
Wed, 11 Mar 2026
ELDN: Tegoprubart advances with strong safety data, phase 3 plans, and cash runway into Q2 2025 - TradingView
Tue, 10 Mar 2026
Eledon Pharma rises on FDA orphan status for lead asset - Seeking Alpha
Tue, 10 Mar 2026
Eledon Pharmaceuticals (ELDN) Gains FDA Orphan Drug Status for T - GuruFocus
Tue, 10 Mar 2026
FDA gives rare-disease status to drug aiming to protect liver transplants - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 80 (M) |
| Shares Float | 54 (M) |
| Held by Insiders | 1 (%) |
| Held by Institutions | 58.5 (%) |
| Shares Short | 6,390 (K) |
| Shares Short P.Month | 6,320 (K) |
| EPS | -1.3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.51 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -44.3 % |
| Return on Equity (ttm) | -95.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -67 (M) |
| Levered Free Cash Flow | -37 (M) |
| PE Ratio | -2.07 |
| PEG Ratio | 0 |
| Price to Book value | 1.76 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.19 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|